Search

Displaying results 841 - 850 of 10000 in total
  1. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although a small handful of regions may

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical

  3. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008. … It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.

  4. Drug

    Gonadorelin

    go.drugbank.com/drugs/DB00644
    ApprovedInvestigationalVet approved

    Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis.

  5. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [A249885] Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. … [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient.

  6. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.

  7. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.

  8. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.

  9. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

    Mixtures: AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 30 ADET, AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 90 ADETCategories: Histamine H1 Antagonists, Non-Sedating
  10. Drug

    Ferrous sulfate anhydrous

    go.drugbank.com/drugs/DB13257
    ApprovedInvestigational

    [A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells.

    Mixtures: Formule No 204 Profil Tab